Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
We analysed contact with physicians, hospital care and actual prescriptions for medication recommended in international guidelines, referring to beta-blockers, ACE inhibitors or angiotensin II receptor blockers, P2Y12-antiplatelet agents, acetylsalicylic acid and statins, one year after myocardial infarction.
|
31371116 |
2020 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
After induction of myocardial infarction (MI) by permanent ligation of the left coronary artery in BALB/c mice, the cardiac function, pulmonary congestion, disease biomarkers, and survival were evaluated using the angiotensin converting enzyme inhibitor enalapril or the loop diuretic furosemide.
|
30738210 |
2019 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical Outcomes at 2 Years Between Beta-Blockade with ACE Inhibitors or ARBs in Patients with AMI Who Underwent Successful PCI with DES: A Retrospective Analysis of 23,978 Patients in the Korea AMI Registry.
|
30788675 |
2019 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACE inhibitor suppresses cardiac remodeling after myocardial infarction by regulating dendritic cells and AT<sub>2</sub> receptor-mediated mechanism in mice.
|
30974387 |
2019 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
|
30948834 |
2019 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Two days after MI, adult male CD1 mice were randomized to three groups, for four to eight weeks of oral treatment with vehicle (MI + vehicle), firibastat (150 mg/kg; MI + firibastat) or the angiotensin I converting enzyme inhibitor enalapril (1 mg/kg; MI + enalapril) as a positive control.
|
30599150 |
2019 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
In patients with hypertension and hypertension with compelling indications, we found no difference in efficacy between ARBs and ACE inhibitors with regard to the surrogate endpoint of blood pressure and outcomes of all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease.
|
29598869 |
2018 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
|
29544929 |
2018 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Carvedilol treatment was a strong predictor for being on target dose of BB at time of implant, as was treatment with angiotensin-converting enzyme inhibitors and/or spironolactone, no history of myocardial infarction, younger age and less pronounced heart failure symptoms.
|
28339659 |
2018 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the mortality of MI has declined dramatically over the past several decades because of advances in medicines (thrombolytic agents, antiplatelet drugs, beta blockers, and angiotensin converting enzyme inhibitors) and approaches to restore tissue perfusion (percutaneous coronary intervention and cardiopulmonary bypass).
|
30465493 |
2018 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Medical therapy for HF after MI includes early (within 24 h) initiation of angiotensin-converting enzyme inhibitors and early (within 7 days) use of aldosterone antagonists.
|
29496021 |
2018 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Neural mechanism of angiotensin-converting enzyme inhibitors in improving heart rate variability and sleep disturbance after myocardial infarction.
|
29859479 |
2018 |
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We identified indications for medication (statins, aspirin, ACE inhibitors, clopidogrel) recommended in UK National Institute for Clinical Excellence (NICE) guidance for CHD (high risk, stable angina, stable angina plus diabetes, unstable angina, and myocardial infarction) and measured the persistence of indicated medication (time from initiation to discontinuation) across quintiles of the Welsh Index of Multiple Deprivation, an area-based measure of socio-economic inequality, using Cox regression frailty models.
|
29522561 |
2018 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge.
|
30130974 |
2018 |
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The ACE D allele is known to increase the risk of malignant ventricular arrhythmias and is also associated with increased QT dispersion after myocardial infarction and hypertension.
|
28575882 |
2017 |
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Additionally, the angiotensin-converting enzyme (ACE) activity in plasma was increased by 33% associated to histological myocardial necrosis.
|
28645882 |
2017 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multiple trials over the past several years have examined the effects of both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in the treatment of left ventricular dysfunction, both acutely after myocardial infarction and in chronic heart failure.
|
28982370 |
2017 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Age [OR = 1.1 (1.03-1.2), p = 0.002], previous MI [OR = 2.2 (1.1-4.4), p = 0.034], angiotensin-converting enzyme inhibitor or angiotensin receptor blocker [OR = 0.5 (0.3-0.9), p = 0.028], and LVEF < 35% [OR = 4.3 (1.9-9.5), p < 0.001] were associated with 1-year mortality.
|
29033508 |
2017 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Blockade of the angiotensin-renin system, with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), has been shown to improve cardiac outcomes following myocardial infarction and delay progression of heart failure.
|
28166592 |
2017 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
At discharge, women less frequently received ACE inhibitors (189 [81.1%] vs. 702 [85.8%], p=0.045) and presented more major adverse events (death, bleeding, infection, myocardial infarction, stent thrombosis or heart failure) during the first month after discharge (10.5% vs. 4.5%, p<0.001) and higher long-term mortality (hazard ratio [HR] 1.6, 95% CI 1.1-2.2).
|
27865662 |
2017 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme inhibitors (ACE-I), are beneficial both in heart failure with reduced ejection fraction (HF-REF) and after myocardial infarction (MI).
|
28577679 |
2017 |
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Randomized, active controlled parallel group trials were included if they compared CCBs with α-blockers, β-blockers, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, or diuretics, had a follow-up of ≥6 months, and had assessments of blood pressure (BP) and CV events [all-cause death, CV death, major CV events (myocardial infarction, MI; congestive heart failure, CHF; stroke; and CV death), MI, stroke, or CHF] in patients with baseline systolic/diastolic BP ≥140/≥90 mm Hg with either concomitant previous stroke and/or CAD.
|
26588586 |
2017 |
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
|
29216228 |
2017 |
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aim to explore the association between ACE I/D polymorphisms and the risk of coronary HD (CHD), coronary artery disease (CAD), and myocardial infarction (MI).
|
26985916 |
2016 |
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We also wanted to examine possible environmental interaction of ACE gene with established cardiovascular risk factors in causation of MI.
|
26687160 |
2016 |